EDGAR Filing Documents for 0001829126-23-004963

Form 8-K - Current report:

SEC Accession No. 0001829126-23-004963

Filing Date

2023-07-28

Accepted

2023-07-27 17:40:04

Documents

Period of Report

2023-07-20

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	titanpharma_8k.htm iXBRL	8-K	43508
2	EXHIBIT 10.1	titanpharma_ex10-1.htm	EX-10.1	325995
3	EXHIBIT 10.2	titanpharma_ex10-2.htm	EX-10.2	13577
4	EXHIBIT 99.1	titanpharma_ex99-1.htm	EX-99.1	7472
	Complete submission text file	0001829126-23-004963.txt		651517

Data Files

Seq	Description	Document	Type	Size
5	XBRL SCHEMA FILE	ttnp-20230720.xsd	EX-101.SCH	3021
6	XBRL LABEL FILE	ttnp-20230720_lab.xml	EX-101.LAB	34240
7	XBRL PRESENTATION FILE	ttnp-20230720_pre.xml	EX-101.PRE	22363
9	EXTRACTED XBRL INSTANCE DOCUMENT	titanpharma_8k_htm.xml	XML	3338

Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080

Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990

TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)